Portal de Periódicos da CAPES

The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors

2011; Elsevier BV; Volume: 40; Issue: 1 Linguagem: Inglês

10.1016/j.ecl.2010.12.001

1558-4410

Ben Lawrence, Björn Gustafsson, Mark Kidd, Anne Couvelard, Bernhard Svejda, Irvin M. Modlin,

Neuroblastoma Research and Treatments

Chromogranin A, although it exhibits limitations, is currently the most useful general tumor biomarker available for use in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). The value of the chromogranin A lies in its universal cosecretion by the majority of neuroendocrine cells that persists after malignant transformation. Clinicians aware of the physiologic role of chromogranin A and its secretion in a variety of non-NET-related pathologic conditions can use this protein as a moderately effective tumor biomarker in the management of GEP-NETs.